Vendor Intelligence Report: Superior Peptides

Published 13 Jun 2026. 18-page investigative report on who is behind Superior Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, Superior Peptides is 4 pass / 0 fail, an overall pass rate of 100%. That headline is real, but narrow: Finnrick coverage currently reaches only Retatrutide, tested from February to April 2026. For buyers seeking Retatrutide, Superior has a defensible independent signal; for BPC-157, TB-500, Semaglutide, HGH, and other catalog items, the report treats the Retatrutide result as non-transferable.

The public-record side is much less complete. California and Texas registry searches did not find a Superior Peptides entity, the storefront points to a Lakeside PO box, and an early-2024 domain/archive trail sits behind the brand. Separate ownership indicators converge on a specific California operator through a WordPress admin email, address, and veteran-founder signals, while a second claimed veteran owner remains unresolved.

The sharpest operational anomaly is in the legal copy: Superior’s privacy and returns terms contained AminoAssylum.shop / Amino Asylum references, alongside a defunct referenced-domain trail the public site does not explain. The report also documents a high buyer-recourse-risk payment model—Zelle, Cash App, and Venmo only—no product-page COAs, and official Reddit posts discussing fake overseas ITPP sourcing and a filler-contaminated sample. Those admissions are not treated as proof against current Retatrutide lots; they are treated as supply-chain transparency evidence buyers should price in.

The resulting read is directional rather than blanket: Superior Peptides is a more evidence-backed Retatrutide option than its sparse public documentation would suggest, but it is not a lab-supported whole-catalog vendor on the supplied record. The full report shows the rating trajectory and methodology sensitivity behind that distinction.

Inside the full report:

  • Retatrutide Finnrick score timeline, methodology-divergence chart, and Appendix A lab data
  • WHOIS and Wayback launch timeline with California and Texas registry dead ends
  • Ownership-attribution exhibits: WordPress admin email, Lakeside PO box, social-profile convergence
  • Privacy-policy and terms captures showing AminoAssylum.shop / Amino Asylum copy carryover
  • Payment-rail, COA-absence, and buyer-recourse analysis from storefront captures
  • Official Reddit-account sourcing admissions and promotion-sweep results

Risk assessment

  • Payment-recourse risk — high: Terms list Zelle, Cash App, and Venmo only; no credit-card processor or chargeback path for non-delivery, wrong item, or substandard product.
  • COA and supply-chain transparency risk — high: No product-page COAs/testing documents were found; Reddit posts by the official account describe fake overseas ITPP sources and a filler-contaminated batch, although Retatrutide has 4 pass / 0 fail in Finnrick testing.
  • Catalog-specific quality uncertainty outside Retatrutide — medium: Finnrick data covers only Retatrutide (4 tests, 4 pass / 0 fail, 82.98%); BPC-157, TB-500, HGH Somatropin, Semaglutide, Tirzepatide and other catalog items lack Finnrick coverage.
  • Corporate-accountability and brand-history opacity risk — medium: No California or Texas entity was found under the searched Superior names, the second claimed owner is unidentified, and legal pages still reference AminoAssylum.shop/Amino Asylum.
  • Regulatory/compliance exposure risk — medium: Catalog includes HGH Somatropin and GLP-1 agonists sold under research-use framing, with only PO-box and peer-to-peer payment infrastructure visible.